Triumvira Immunologics announced a strategic relationship with the Centre for Commercialisation of Cancer Immunotherapy (C3i). Under the terms of the agreement, C3i will deliver cell therapy products for Triumvira’s global Phase 1 and 2 clinical trials and has committed to underwrite an investment in the company.
“We are very pleased to be working with C3i for the manufacturing at the Centre of Excellence in Cellular Therapy (CETC) GMP manufacturing facility. It is critical for us to have a supplier with specific expertise in cellular therapies, including cancer immunotherapies,” said Paul Lammers, MD, MSc, President & CEO, Triumvira. “As we work toward our goal of entering clinical development in 2019, we understand the importance of securing sufficient product from a state-of-the-art facility.”
As part of the deal, C3i also obtained a license to commercialize Triumvira's lead product candidate, CD19 TAC, in Canada. “As part of the C3i mission, we not only build long-term partnerships but also ensure that the Canadians will have access to innovative technologies” commented Louisa Petropoulos, Director of Business Development at C3i.
“We are honored to be supporting Triumvira Immunologics in their drug development program. Their selective and targeted approach to treat cancer aligns well with our manufacturing expertise as well as our commitment to bringing new treatment options to patients with cancer,” Francois Bettez, President & CEO of C3i, said.
The Centre of Excellence for Cellular Therapy (CETC), located at Hôpital Maisonneuve-Rosemont in Montreal, is a fully operational cGMP manufacturing facility for cellular therapies, including cancer immunotherapies and regenerative medicine. It is the only operational GMP validated center in Canada with commercial capacity, and is compliant with EMA, FDA and Health Canada regulatory requirements.